Our commercial disputes litigators help leaders in the energy, life sciences and healthcare, financial, food and beverage, and other industries to minimize or eliminate the risk from contract and commercial disputes, business torts, and unfair business practice and other business litigation.
Our Contracts and Business Torts team has an established record of successfully resolving a wide variety of issues through trial, arbitration and appeal across consumer class actions, energy litigation and other representative matters. Our cross-firm, multidisciplinary team forms the backbone of a “Litigation Powerhouse” (according to Law360) that tries high-exposure cases; coordinates complex, multiparty dispute resolutions; applies industry-specific expertise; resolves cases pretrial as appropriate; manages public scrutiny; and is backed by dedicated, state-of-the-art discovery resources.
Our lawyers work on behalf of our clients to resolve business disputes involving a wide range of commercial contracts. These include disputes related to the purchase and sale of businesses, utility contracts, contracts for the sale or development of intellectual property, construction contracts and partnership disputes. We leverage our experience in litigating cases under the Uniform Commercial Code including contracts for the sale of goods, security interests, loan transactions, banking procedures and investment, to help companies and individuals advance their commercial interests.
Our business tort lawyers regularly assist clients in resolving cases involving allegations of improper conduct in business transactions, including fraud, negligent misrepresentation, interferences with contractual or economic relations, and bad faith and unfair dealing. We have an established track record of representing clients in cases involving claims under special statutes, such as federal and state RICO laws, consumer protection laws and laws relating to unfair trade practices.
November 27, 2017
Joe Akrotirianakis, Aaron Craig and Jeff Bucholtz counsel Allergan on two "seminal" lawsuits that will test the extent to which drug compounders can mass-produce virtual copies of brand-name prescription drugs